Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer

  • Technology appraisal guidance
  • TA227
  • Published: 
Download guidance (PDF)

6 Related NICE guidance

Published

  • Lung cancer. NICE clinical guideline 121 (2011). Available from www.nice.org.uk/guidance/CG121

  • Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 192 (2010). Available from www.nice.org.uk/guidance/TA192

  • Pemetrexed for the maintenance treatment of non-small-cell lung cancer. NICE technology appraisal guidance 190 (2010). Available from www.nice.org.uk/guidance/TA190

  • Pemetrexed for the first-line treatment of non-small-cell lung cancer. NICE technology appraisal guidance 181 (2009). Available from www.nice.org.uk/guidance/TA181

  • Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal). NICE technology appraisal 175 (2009). Available from www.nice.org.uk/guidance/TA175

  • Erlotinib for the treatment of non-small-cell lung cancer. NICE technology appraisal guidance 162 (2008). Available from www.nice.org.uk/guidance/TA162

  • Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal). NICE technology appraisal 148 (2008). Available from www.nice.org.uk/guidance/TA148

  • Pemetrexed for the treatment of non-small-cell lung cancer. NICE technology appraisal guidance 124 (2007). Available from www.nice.org.uk/guidance/TA124

  • National Institute for Health and Care Excellence (NICE)